Clinical Trial

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Name: Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study. — clinical trial record (NCT06162377)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks before surgery.

Trial Details

NCT Number	NCT06162377
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Head and Neck Squamous Cell Carcinoma
Enrollment	25 participants
Start Date	2024-01-10
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-10